Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03370848 · ClinicalTrials.gov registry record · Phase 4
Effects of Psyllium on Niacin Tolerability
A Phase 4 study of Dyslipidemias and Hyperlipidemias, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03370848: Completed Phase 4 study of Dyslipidemias and Hyperlipidemias, sponsored by VA Greater Los Angeles Healthcare System.
NCT03370848 is a Phase 4 study of Dyslipidemias and Hyperlipidemias that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 26 participants, below the 232-participant average among 28 other Dyslipidemias trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03370848, a Phase 4 study of Dyslipidemias and Hyperlipidemias, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether psyllium is effective in reducing flushing due to niacin and also to measure the effect of niacin on cholesterol levels.
Conditions Studied
Interventions
- DRUG Aspirin
- DIETARY_SUPPLEMENT Psyllium
Study Locations (1)
California
- VA West Los Angeles Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
What the finished NCT03370848 record still lists
NCT03370848 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 232-participant average among 28 other Dyslipidemias trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Dyslipidemias appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.
NCT03370848 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03370848 about?
NCT03370848 is a clinical study titled "Effects of Psyllium on Niacin Tolerability". The purpose of this study is to determine whether psyllium is effective in reducing flushing due to niacin and also to measure the effect of niacin on cholesterol levels.
What is the current status of trial NCT03370848?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2009-03. Estimated completion is 2011-07.
What conditions does trial NCT03370848 study?
This clinical trial studies the following conditions: Dyslipidemias, Hyperlipidemias, Flushing.
What interventions are being tested in trial NCT03370848?
The interventions under investigation include: Aspirin (DRUG), Psyllium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03370848?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03370848 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03370848's enrollment target sits among peer trials
26 27th of 28 higher than 2 of 28 other Dyslipidemias trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemias trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
'Ai Pono Cooking Demonstrations
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
-
Military Health and Nutrition Examination Study
RECRUITING
-
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia